Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions

Table 1

Asessment of clinical trials by tumor/DC fusions-based vaccine.

	Tumor/DC Fusions			Patient	Clinical
Tumor	Tumor Cells	Dendritic Cells	Coadministration	Number	Responses	Ref.
Melanoma	Autologous	Allogeneic		16	1 (CR)	[135]
					1 (PR)	[136]
					5 (SD)
					9 (PD)
	Autologous	Autologous		17	1 (PR)	[137]
					1 (SD)
					15 (PD)
	Autologous	Allogeneic		13	8 (SD)	[138]
					3 (SD)
					2 (N)
	Autologous	Autologous	rh IL-12	4	4 (PD)	[23]
	Autologous	Allogeneic	rh IL-2	11	1 (SD)	[139]
					10 (PD)
Glioma	Autologous	Autologous		8	2 (PR)	[23]
					1 (SD)
					5 (PD)
	Autologous	Autologous	rh IL-12	12	3 (PR)	[24]
					2 (MR)
					4 (SD)
					3 (PD)
Renal cell carcinoma	Autologous	Allogeneic		22	14 (SD)	[138]
					2 (PD)
					3 (OR)
					3 (N)
	Autologous	Autologous		13	5 (SD)	[142]
					8 (PD)
	Autologous	Allogeneic		20	2 (PR)	[143]
					8 (SD)
					10 (PD)
	Allogeneic	Allogeneic		8	3 (SD)	[144]
					5 (PD)
	Autologous	Allogeneic		4	1 (SD)	[144]
					3 (PD)
	Autologous	Allogeneic		10	1 (PR)	[145]
					6 (SD)
					3 (PD)
Breast cancer	Autologous	Autologous		10	2 (PR)	[142]
					1 (SD)
					7 (PD)
	Autologous	Autologous	rh IL-12	2	1 (SD)	[24]
					1 (PD)
Gastric/Colorectal cancer	Autologous	Autologous	rh IL-12	3	1 (SD)	[24]
					2 (PD)
Hepatocellular carcinoma	Autologous	Autologous		1	1 (PD)	[118]
Ovarian cancer	Autologous	Autologous	rh IL-12	3	2 (SD)	[24]
					1 (PD)

CR: complete response; PR: partial response; MR: mixed response; SD: stable disease; PD: progressive disease.
OR: objective response; N: not evaluated.